Search research articles
Contact Us
Filters
Showing results (101-110 of 243) with videos related to
Page
of 25
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Romain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer
Nermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 1, 2017
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids
Ivana Sullivan, Gwénaël Le Teuff, Joël Guigay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer
David Planchard, Michael J Boyer, Jong-Seok Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Adrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Cancer Research
|
May 3, 2017
Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Patients
Emma Pailler, Marianne Oulhen, Isabelle Borget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2026
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX
Marco Tagliamento, Marco Bruzzone, Eva Blondeaux, et al.
Neuroendocrinology
|
October 23, 2019
Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?
Julien Hadoux, Pierre Blanchard, Jean-Yves Scoazec, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 24, 2021
Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study
Diane Boinon, Cécile Charles, Léonor Fasse, et al.
Page
of 25
Search research articles
Search
Showing results (101-110 of 243) with videos related to
Sort By:
Page
of 25
European Journal of Nuclear Medicine and Molecular Imaging
|
November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Romain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer
Nermine S Kamal, Jean-Charles Soria, Jean Mendiboure, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 1, 2017
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids
Ivana Sullivan, Gwénaël Le Teuff, Joël Guigay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer
David Planchard, Michael J Boyer, Jong-Seok Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Adrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Cancer Research
|
May 3, 2017
Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Patients
Emma Pailler, Marianne Oulhen, Isabelle Borget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2026
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX
Marco Tagliamento, Marco Bruzzone, Eva Blondeaux, et al.
Neuroendocrinology
|
October 23, 2019
Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?
Julien Hadoux, Pierre Blanchard, Jean-Yves Scoazec, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 24, 2021
Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study
Diane Boinon, Cécile Charles, Léonor Fasse, et al.
Page
of 25